Icatibant Acetate is the acetate salt form of icatibant, an antagonist of the human bradykinin B2 receptor (B2R).
CAT No: HB00111
CAS No:138614-30-9
Synonyms/Alias:Icatibant acetate;Firazyr;Hoe-140;138614-30-9;Icatibant (acetate);Icatibant acetate [USAN];UNII-325O8467XK;Hoechst 140;325O8467XK;HOE 140;HOE140;(R)-Arginyl-(S)-arginyl-(S)-prolyl-(2S,4R)-(4-hydroxyprolyl)glycyl-(S)-(3-(2-thienyl)alanyl)-(S)-seryl-(R)-((1,2,3,4-tetrahydro-3-isoquinolyl)carbonyl)-(2S,3aS,7aS)-((hexahydro-2-indolinyl)carbonyl)-(S)-arginine acetate (salt);ICATIBANT ACETATE (MART.);ICATIBANT ACETATE [MART.];L-ARGININE, D-ARGINYL-L-ARGINYL-L-PROLYL-(4R)-4-HYDROXY-L-PROLYLGLYCYL-3-(2-THIENYL)-L-ALANYL-L-SERYL-(3R)-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBONYL-(2S,3AS,7AS)-OCTAHYDRO-1H-INDOLE-2-CARBONYL-, ACETATE;L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-, acetate (salt);Hoechst-140;Icatibant acetate?;(R)-Arginyl-(S)-arginyl-(S)-prolyl-(2S,4R)-(4-hydroxyprolyl)glycyl-(S)-[3-(2-thienyl)alanyl]-(S)-seryl-(R)-[(1,2,3,4-tetrahydro-3-isoquinolyl)carbonyl]-(2S,3aS,7aS)-[(hexahydro-2-indolinyl)carbonyl]-(S)-arginine acetate (salt);JE-049;SAJAZIR;JE049;ICATIBANT ACETATE [MI];ICATIBANT ACETATE [JAN];CHEMBL2028852;ICATIBANT ACETATE [WHO-DD];138614-30-9 , xAcetate;AKOS040745043;ICATIBANT ACETATE [ORANGE BOOK];DA-54232;MS-32135;HY-108896;CS-0031296;Q27256146;(R)-arginyl-(S)-arginyl-()-prolyl-(2S,4R)-(4-hydroxyprolyl)glycyl-(S)-(3-(2-thienyl)alanyl)-(S)-seryl-(R)-((1,2,3,4-tetrahydro-3-isoquinolyl)carbonyl)-(2S,3aS,7aS)-((hexahydro-2-indolinyl)carbonyl)-(S)-arginine acetate;D-Arginyl-L-arginyl-L-prolyl-(R)-4-hydroxy-L-prolylglycyl-3-(thiophen-2-yl)-L-alanyl-L-seryl-(R)-((1,2,3,4-tetrahydroisoquinolin-3-yl)carbonyl)-(2S,3aS,7aS)-((hexahydroindolin-2-yl)carbonyl)-L-arginine triacetate;L-ARGININE, D-ARGINYL-L-ARGINYL-L-PROLYL-TRANS-4-HYDROXY-L-PROLYLGLYCYL-3-(2-THIENYL)-L-ALANYL-L-SERYL-D-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBONYL-L-(2.ALPHA.,3A.BETA.,7A.BETA.)-OCTAHYDRO-1H-INDOLE-2-CARBONYL-, ACETATE (SALT);
Icatibant Acetate, a synthetic decapeptide and potent bradykinin B2 receptor antagonist, is a specialized carbohydrate compound widely utilized in biochemical and pharmacological research. Engineered to mimic the structure of naturally occurring peptides, Icatibant Acetate exhibits high specificity and affinity for its target receptor, making it a valuable tool for investigating the intricate mechanisms of bradykinin-mediated pathways. Its robust peptide backbone, coupled with chemical stability and solubility in aqueous solutions, allows for seamless integration into a variety of experimental settings. Researchers benefit from its well-characterized pharmacological profile, which has been thoroughly explored in both in vitro and in vivo models, providing reliable and reproducible results. The unique properties of Icatibant Acetate render it indispensable for elucidating the physiological and pathological roles of bradykinin, especially in contexts where modulation of vascular permeability, inflammation, and pain signaling is of interest.
Inflammation Research: As a selective bradykinin B2 receptor antagonist, Icatibant Acetate is extensively employed in studies aiming to dissect the molecular underpinnings of inflammatory responses. By blocking the interaction between bradykinin and its receptor, the compound enables researchers to delineate the downstream signaling events involved in edema formation, leukocyte recruitment, and cytokine release. This targeted inhibition facilitates the exploration of novel anti-inflammatory strategies and helps identify potential therapeutic targets for inflammatory diseases. Investigators often utilize Icatibant Acetate in cell-based assays and animal models to assess the contribution of bradykinin signaling to acute and chronic inflammation, advancing the understanding of complex immune processes.
Vascular Permeability Studies: The modulation of vascular permeability is a critical aspect of many physiological and pathological conditions, and Icatibant Acetate serves as an essential tool for probing this phenomenon. By antagonizing bradykinin B2 receptors, the compound allows for precise evaluation of bradykinin-induced increases in endothelial permeability. This application is particularly relevant in studies investigating the mechanisms underlying tissue swelling, plasma extravasation, and barrier function in various organ systems. Researchers leverage Icatibant Acetate to differentiate between bradykinin-dependent and independent pathways, providing valuable insights into the regulation of vascular integrity.
Pain Mechanism Exploration: Icatibant Acetate's ability to inhibit bradykinin signaling makes it a powerful agent for studying pain pathways at the molecular and cellular levels. Bradykinin is a well-known mediator of nociception, and its interaction with B2 receptors is implicated in the sensitization of sensory neurons. By blocking this interaction, Icatibant Acetate enables researchers to investigate the processes involved in pain perception, hyperalgesia, and allodynia. Experimental models utilizing the compound have contributed to the identification of key molecular players in pain signaling, supporting the development of innovative approaches to pain management.
Allergy and Hypersensitivity Models: The role of bradykinin in allergic and hypersensitivity reactions is a prominent area of research, and Icatibant Acetate is frequently incorporated into experimental protocols to clarify this role. Its antagonistic action on B2 receptors helps to unravel the contribution of bradykinin to symptoms such as vasodilation, increased vascular permeability, and smooth muscle contraction. Studies utilizing Icatibant Acetate have enhanced the understanding of the interplay between bradykinin and other mediators of allergic responses, aiding in the identification of potential intervention points for modulating hypersensitivity.
Signal Transduction Pathway Analysis: In addition to its applications in inflammation, vascular biology, pain, and allergy research, Icatibant Acetate is instrumental in broader signal transduction studies. Researchers employ the compound to dissect the specific signaling cascades activated by bradykinin B2 receptor engagement, including G protein-coupled receptor pathways, second messenger systems, and downstream effectors such as protein kinases and transcription factors. By selectively inhibiting bradykinin signaling, Icatibant Acetate provides a unique means to map out complex cellular networks and to differentiate between overlapping pathways activated by related peptides. This comprehensive approach supports the identification of novel molecular targets and enhances the overall understanding of cell signaling dynamics in health and disease.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More